An anti–IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results
Authors:
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 146 (2) , 367-376.e3
Abstract
No abstract availableKeywords
Funding Information
- Celgene
- Celgene Corporation
This publication has 34 references indexed in Scilit:
- Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading systemGut, 2012
- Eosinophilic esophagitis: Epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatmentJournal of Allergy and Clinical Immunology, 2012
- Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: A prospective studyJournal of Allergy and Clinical Immunology, 2011
- IL-13 Induces Esophageal Remodeling and Gene Expression by an Eosinophil-Independent, IL-13Rα2–Inhibited PathwayThe Journal of Immunology, 2010
- Interleukin‐13: prospects for new treatmentsClinical & Experimental Allergy, 2009
- Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroidsAllergy, 2009
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoidsJournal of Allergy and Clinical Immunology, 2007
- Persistent Effects Induced by IL-13 in the LungAmerican Journal of Respiratory Cell and Molecular Biology, 2006
- Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrixProceedings of the National Academy of Sciences, 2006